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Abstract 
Glaucoma is the most common optic neuropathy in humans and the leading cause of irreversible 
blindness worldwide. Its prevalence and incidence increase exponentially with ageing and raised 
intraocular pressure (IOP), while increasing evidence suggests that systemic mitochondrial 
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abnormalities may also be implicated in its pathogenesis. We have recently shown that patients who 
have not developed glaucoma despite being exposed for many years to high IOP (ocular 
hypertension - OHT) have more efficient mitochondria, measured in peripheral blood lymphocytes, 
when compared to age-similar controls and fast progressing normal tension glaucoma (NTG) 
patients. In this prospective case series we aimed to explore some of the molecular pathways 
involved in mitochondrial efficiency in glaucoma resistance by measuring  the systemic activity (in 
peripheral blood) of key mitochondrial regulators: the mammalian target of rapamycin (mTOR) and 
its major upstream regulators and downstream effectors that form the PTEN-Akt1-mTOR signalling 
pathway. We found no statistically significant difference in the systemic mTOR activity between the 
three groups (control, NTG and OHT). In line with the mTOR results, there was no significant 
difference in the activity of both the two major upstream mTOR regulators (PTEN and Akt1) and its 
two main downstream effectors (S6K and 4EBP1). In a single NTG patient, with history of Raynaud’s, 
significantly higher mTOR activity was noted. We conclude that the PTEN-Akt1-mTOR pathway does 
not appear to play a central role in mitochondrial efficiency in OHT. 
 
Introduction 
Worldwide, glaucoma is responsible for more blindness than any other eye condition, except 
cataract. Data from population-based surveys indicate that 1 in 40 adults older than 40 years has 
glaucoma with loss of visual function, which equates to 60 million people worldwide being affected; 
this number is constantly rising as the population ages (Quigley 2011). 
Raised intraocular pressure (IOP) is the major risk factor for glaucoma, but patients with glaucoma 
deteriorate at all levels of IOP, strongly suggesting that this condition is multifactorial. The second 
most important established risk factor for the development and progression of glaucoma, 
consistently identified from large prospective clinical trials (Nouri-Mahdavi 2004, Leske 2007) and 
epidemiological studies (Mitchell 1996, Leske 2008), is increasing age. The increase in the prevalence 
of glaucoma with age is not accounted for by any increase in IOP with ageing (Klein 1992, Varma 
2004), suggesting that ageing independently confers increased susceptibility to the disease. 
Based on the well-established link between ageing and systemic mitochondrial functional decline, 
increasing evidence suggests that systemic mitochondrial abnormalities may be implicated in the 
pathogenesis of a range of neurodegenerative diseases (Lin 2006), including Parkinson’s disease 
(Schapira 2012), Alzheimer’s disease and glaucoma (Kong 2009, Lascaratos 2012). Indeed, a maternal 
family history of primary open angle glaucoma (POAG) is more likely than a paternal family history, 
suggesting a possible mitochondrial genetic influence (Nemesure 1996). The mean systemic 
mitochondrial respiratory activity, as measured in the peripheral blood, was significantly lower in 27 
POAG patients compared to 64 control subjects (Abu-Amero 2006). Also, lymphoblasts from POAG 
patients have been shown to exhibit a defect in complex I of the oxidative phosporylation (oxphos) 
pathway, leading to decreased rates of respiration and ATP production (Lee 2012). In the presence 
of multiple cellular stressors, as seen in a multifactorial disease like glaucoma, it is possible that such 
generalised (systemic) mitochondrial abnormalities may accentuate any underlying elements of 
localised bioenergetic crisis at the level of the retinal ganglion cells (RGCs) and lead to increased 
susceptibility to cell death. 
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We have recently shown that patients ‘resistant’ to the major risk factor (raised IOP) for glaucoma 
have more efficient mitochondria, measured in peripheral blood lymphocytes, when compared to 
age-similar controls and fast progressing glaucoma patients (Lascaratos 2015). In line with these 
findings, efficient mitochondrial biogenesis has also been reported to drive incomplete penetrance 
in Leber’s hereditary optic neuropathy carriers (Giordano 2014), while increased oxphos activity has 
been linked with vision preservation in autosomal dominant optic atrophy (ADOA) patients (Van 
Bergen 2011).  
This study aims to explore the molecular pathways involved in mitochondrial efficiency in glaucoma 
resistance by measuring, to our knowledge for the first time, the systemic activity of key 
mitochondrial regulators, the mammalian target of rapamycin (mTOR) and its major upstream 
regulators and downstream effectors that form the PTEN-Akt1-mTOR signalling pathway, in the 
peripheral blood mononuclear cells (PBMCs) from a unique cohort of patients at the extremes of IOP 
susceptibility: normal tension glaucoma (NTG) patients with fast visual field (VF) progression (Mean 
Deviation change worse than -1.0 dB/yr) despite a low mean IOP (12.9mmHg) over a median follow-
up of 6 years, and ocular hypertension (OHT) patients with no or minimal VF progression despite a 
relatively high mean IOP (24.5mmHg) over a median of 8 years. Age-similar subjects with normal 
IOP, healthy discs and no family history of glaucoma were also recruited as controls.  
mTOR is a multi-domain, highly conserved serine/threonine kinase that controls cell growth and 
metabolism in response to nutrients, growth factors, cellular energy and stress (Khalil 2012). mTOR 
is a key regulator of mitochondrial function (Morita 2013) and co-localises with the outer 
mitochondrial membrane (Desai 2002). mTOR suppression has been found to result in increased 
autophagy, reduced mitochondrial function (Ramanathan 2009) and decreased mitochondrial 
respiration (Schieke 2006). This direct effect of mTOR on mitochondrial function is thought to be 
mediated to a certain extent by its ability to form complexes with the mitochondrial outer 
membrane proteins Bcl-xl (B-cell lymphoma-extra large) and VDAC1 (voltage-dependent anion-
selective channel protein 1) (Ramanathan 2009). The potentially important role of mTOR in the eye 
has been demonstrated in adult mice, where mTOR activity is suppressed (Di Polo 2015) and protein 
synthesis is impaired following axotomy of the RGCs (Verma 2005). mTOR has also been shown to 
affect cellular metabolism by means of the transcriptional control of mitochondrial oxidative 
function through the YY1-PGC1α (yin-yang 1-peroxisome-proliferator-activated receptor co-activator 
1α) transcriptional complex (Cunningham 2007).  
Based on this link between mTOR activity and mitochondrial function, and to better understand the 
extent to which this kinase is involved in mitochondrial efficiency in OHT, we also measured the 
systemic activity of the main mTOR upstream regulators [PTEN (phosphatase and tensin homologue) 
and Akt1 (also known as PKBα, protein kinase B alpha)], as well as its major downstream effectors 
[S6K (p70 ribosomal protein S6 kinase) and 4EBP1 (eukaryotic translation-initiation factor 4E-binding 
protein 1)]. PTEN is a negative regulator of the mTOR pathway (Bossy-Wetzel 2004) by opposing 
phosphoinositide 3-kinase (PI3K) function and leading to inactivation of Akt1 and mTOR signalling 
(Figure 1). Akt1 can activate mTOR by mediating the inhibitory phosphorylation of its negative 
regulators TSC2 (tuberous sclerosis protein 2) and PRAS40 (proline-rich Akt/PKB substrate 40 kDa) 
(Song 2012). mTOR phosphorylates S6K and 4EBP1 to activate protein translation and cell survival 
(Gingras 2004).  
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Methods 
 
Reagents 
Reagents were supplied by Sigma–Aldrich (Poole, UK) and Merck (Nottingham, UK), unless otherwise 
stated. 
 
Patient selection 
Two cohorts of 7 subjects with ≥8 visual fields over ≥5 years of follow-up were recruited 
prospectively from Moorfields Eye Hospital: a) NTG group: rapidly progressing patients with Mean 
Deviation change > -1.0 dB/yr and mean IOP<16; b) OHT group: non- or slowly progressing patients 
with mean IOP>24. As mitochondrial function is known to decline with ageing, a third cohort of an 
equal number of age-similar subjects with normal IOP, healthy discs and no family history of 
glaucoma was recruited as controls. Since this was an exploratory study with carefully selected 
individuals at the very extremes of IOP susceptibility, no power calculation to determine the sample 
size was performed. 
 
Schedule of investigations 
Clinical phenotyping of all 21 participants included detailed medical history, fundus examination, IOP 
measurement using Goldmann applanation tonometry, measurement of central corneal thickness 
(CCT) with an ultrasound pachymeter (DGH Technology Inc, Exton, PA), and automated perimetry 
with the Swedish interactive threshold algorithm standard 24-2 program. 24-hour ambulatory blood 
pressure was measured with the Welch Allyn Ambulatory Blood Pressure Monitor 6100 (Aston 
Abbotts, Buckinghamshire, UK). Height and weight were also measured with participants wearing 
light clothing and no footwear. Peripheral blood was collected from each participant and processed 
for the isolation of unstimulated PBMCs and experimental analysis.  
 
Isolation of human PBMCs 
PBMCs were isolated from anticoagulated peripheral blood using Lymphoprep (Axis-Shield, Oslo, 
Norway), as described previously (Thorsby 1970) and resuspended in phenol red-free RPMI 1640 
medium supplemented with 2mM glutamax, 12.5mM HEPES, 50U/mL penicillin and 50μg/mL 
streptomycin, to a density of 1 × 106/ml. 1ml was required for each of the 5 ELISA measurements 
described below. 
 
Raji cell line 
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This well established immortalised human B- lymphocyte cell line was used as a reference (internal 
control) in the measurements of mitochondrial content by porin. Raji cells were cultured in RPMI 
1640 medium, supplemented with 10% FCS, 2mM glutamax, 12.5mM HEPES, 50U/mL penicillin and 
50μg/mL streptomycin in 75-cm2 flasks at 37°C in an atmosphere of 5% CO2. Doubling time was 
approximately 20 hours and cells were generally passaged at a 1:8 ratio and maintained at a density 
of 1 × 106/ml for use in experiments. 
 
ELISA 
mTOR is known to be phosphorylated at Ser2448 via the PI3 (phosphoinositide 3)-kinase/Akt1 
signalling pathway. The PathScan Total mTOR and Phospho-mTOR (Ser2448) Sandwich enzyme-
linked immunosorbent assay (ELISA) kits were used to measure total and phospho-mTOR (one 
measurement per participant), respectively. In order to maintain the phospho-activity, PBMCs 
immediately after isolation were resuspended in RPMI, washed in PBS and resuspended in 100μl of 
lysis buffer. The lysate was then microcentrifuged at 15,000 x g for 10 min at 4°C and 100μl of the 
supernatant added into each well of a 96-well plate pre-coated with mTOR mouse antibody, sealed 
with tape and incubated at 4°C overnight. After washing twice with wash buffer, 100μl of mTOR 
rabbit antibody were added to each well to detect the captured mTOR protein. After a second 
incubation at 37°C for 1hr and repeat wash, 100μl of anti-rabbit IgG, horseradish peroxidase (HRP)-
linked antibody was added to each well to recognise the bound detection antibody. The plate was 
incubated at 37°C for 30min, washed as previously and 100μl of tetramethylbenzidine (TMB) 
substrate was added to each well, in order to develop the colour (blue). The reaction was terminated 
by the addition of an acidic STOP solution, changing the solution colour from blue to yellow. The 
absorbance was measured with a plate reader at 450nm, and mTOR activity was expressed as the 
ratio between Phospho-mTOR (Ser2448) and Total mTOR.  
 
ADP Phosporylation 
This assay provides a useful measure of mitochondrial function, and is designed to measure 
complex-specific ATP synthesis in live cells over a given period of incubation time, based on the 
exogenous supply of substrates. The rate of substrate-linked ADP phosphorylation for the different 
mitochondrial complexes was measured in digitonin permeabilised cells, as described previously by 
our group (Korlipara 2004). Live cells were harvested and resuspended in incubation medium 
containing 150mM KCl, 2mM K2EDTA, 10mM K2HPO4, 5mM Tris base, pH: 7.4 at a concentration of 1 
× 106 cells/ ml. The reaction, performed in triplicate for each participant, was initiated at 37°C by 
mixing 250μl of cells with 250μl of incubation medium containing ADP (1mM), digitonin (20 μg/ml), 
and the following substrates: In the case of complex I, glutamate (10 mM) and malate (10 mM), and 
for complex II succinate (10 mM) and rotenone (10 μM). After 20 minutes of incubation in a rotating 
rack, the reaction was stopped with perchloric acid and this neutralised with 3M K2CO3/0.5M 
triethanolamine. ATP levels were measured using the ATP Bioluminesence Assay kit CLSII (Roche; 
Mannheim, Germany) and the emitted luminescence was measured with a Jade tube luminometer 
(Labtech; Uckfield, UK). Background levels of ATP, in the absence of substrate, were measured in 
duplicate for each participant and subtracted from the complex-specific ATP measurements. Protein 
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levels were estimated using a bicinchoninic acid (BCA) kit (Pierce Thermo Fisher; Basingstoke, UK) 
with reference to the protein standard supplied with the kit. Data were expressed as pmol ATP 
synthesised/min/mg protein and represent means of four analyses per sample. 
 
Western blot analysis 
Cells were harvested, washed with PBS and processed as described previously by our group (Cleeter 
2013). 25–40 μg of whole cell lysates were electrophoresed on Novex gels (NuPage 4–12%; 
Invitrogen, Paisley, UK), transferred onto polyvinylidene fluoride membrane (Millipore; Watford, UK) 
and then probed with antibodies to porin (Abcam, Cambridge, UK; 1/1000 dilution). All were 
normalised to β-actin (Abcam, Cambridge, UK; 1/5000 dilution). Blots were developed using an 
enhanced chemiluminescence (ECL) kit (GE Healthcare; Little Chalfont, UK) and exposed to X-ray film 
(GE Healthcare). The film was developed and signal intensities in the linear range were quantified by 
the ‘Alphadigidoc’ software package (AlphaInnotech; San Leandro, CA). The densitometric reading of 
the protein of interest was expressed as a percentage of the control gene product (β -actin). 
 
Statistical analysis 
The Wilcoxon signed rank test was used for comparisons between pairs of groups. For comparisons 
between all three groups (control, NTG, OHT), the Kruskal Wallis test was used as the equivalent of 
one-way non-parametric ANOVA. Clinical data are presented as mean ± standard deviation (SD) for 
normally distributed measures and as median ± interquartile range (IQR) for data that are not 
normally distributed. In all experiments a P value of <0.05 was generally considered statistically 
significant. 
In the box-and-whisker plots (IBM SPSS software, version 21.0), the middle (horizontal) line 
represents the median. The lower and upper horizontal lines of each box represent the lower and 
upper quartile values, respectively. The difference between the lower and upper quartiles is the 
interquartile range (IQR). Results are presented as median (IQR) for each parameter (n=7 from each 
group); NS: not significant. Outliers are highlighted with a circle or asterisk on the box-and-whisker 
plot. 
 
Ethical approval 
Consent was obtained from all the participants in this study and the relevant Research Ethics 
Committee approval (REC Ref: 11/H0715/10) was granted. This study adhered to the tenets of the 
Declaration of Helsinki. 
 
 
Results 
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Baseline clinical data and past medical history (Tables 1 and 2) 
The mean age (years) of the participants was almost identical between the NTG (70.7) and OHT 
(70.6) groups, and very similar to the controls (65.3). The median rate of VF progression for the 
whole field over the follow-up period, measured with the Moorfields Progressor software, was -
1.07dB/year (IQR -1.05 to -1.09) in the NTG group (selected to represent a fast-progressing group), 
while the median rate only for the VF progressing points was even faster at -2.80dB/year (IQR -2.60 
to -3.35). The OHT cohort showed minimal progression with a median rate of -0.15dB/year (IQR -
0.14 to -0.21). All the OHT patients had full VFs. A significant number of VFs was performed in the 
NTG (median 9, range 8-15) and OHT (median 8, range 8-13) groups to provide sufficient information 
for representative progression measurements. Importantly, despite the fast disease progression, the 
mean IOP in the NTG group over 6 years of follow-up was only 12.9mmHg. In the OHT group, despite 
the minimal VF progression, the mean IOP over 8 years of follow-up was 24.5mmHg. The mean CCT 
was higher in the OHT group (574.9μm) and lower in the NTG group (525.8μm), as compared to the 
controls (550.4μm). The mean cup-to-disc ratio in the OHT subjects was 0.56 and in the controls 
0.36, while the NTG group showed advanced cupping with a mean cup-to-disc ratio of 0.91. None of 
the 21 study participants reported a history of smoking or excessive alcohol intake, or suffered from 
active haematological malignancy or infection at the time of the blood sampling or had undergone 
recent chemotherapy, factors which if present might have negatively influenced mitochondrial 
function in the PBMC. 
 
Higher systemic mitochondrial activity in ‘extreme’ OHTs as compared to NTGs  
The rate of ADP phosphorylation by mitochondrial respiratory complex I and complex II was 
significantly higher in the lymphocytes of OHT patients, as compared to the NTG group (Figure 2). 
The median (IQR) rate of ADP phosphorylation by complex I in the control, NTG and OHT groups, was 
4712 (3856-7732), 6063 (3016-8649) and 11237 (5716-12576), respectively (P=0.063 between 
control-OHT, P=0.018 between NTG-OHT and P=0.866 between control-NTG). The median (IQR) rate 
of ADP phosphorylation by complex II in the control, NTG and OHT groups, was 6712 (3962-8472), 
7018 (3077-9897) and 11277 (6131-12285), respectively (P=0.128 between control-OHT, P=0.018 
between NTG-OHT and P=0.612 between control-NTG). There was no significant difference in the 
porin levels, an established marker of mitochondrial content and the most abundant protein in the 
mitochondrial outer membrane, in the lymphocytes between the three groups, with the median 
(IQR) porin level in the control, NTG and OHT groups, being 28.5 (27.8-30.0), 27.7 (26.0-30.0) and 
30.0 (28.3-31.1), respectively. 
 
Systemic mTOR activity is similar between ‘extreme’ NTGs, ‘extreme’ OHTs and controls 
In this small, but carefully selected cohort, there was no difference in the mTOR activity between the 
three groups (Figure 3). The median (IQR) systemic mTOR activity in the control, NTG and OHT 
groups, was 0.33 (0.17 to 0.42), 0.23 (0.16 to 0.28) and 0.19 (0.18 to 0.30), respectively. Activation of 
the mTOR pathway is known to mediate vasospastic phenomena (Zhang 2012) and of speculative 
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interest is that the only patient in our cohort with history of Raynaud’s phenomenon (NTG no 6) had 
mTOR activity much higher (0.52) compared to the other patients in the cohort (outlier in Figure 3). 
 
mTOR upstream regulator and downstream effector activity is similar between the three groups 
In line with the mTOR results, there was no significant difference in the systemic activity of both the 
two major upstream mTOR regulators (PTEN and Akt1) forming the PTEN-Akt1-mTOR pathway 
(Figure 3) or the two main mTOR downstream effectors (S6K and 4EBP1) (Figure 4). In more detail, 
the median (IQR) PTEN activity in the NTG, OHT and control groups, was 0.45 (0.36 to 0.58), 0.48 
(0.37 to 0.99) and 0.49 (0.36 to 0.70), respectively, while the median (IQR) Akt1 activity was 0.18 
(0.14 to 0.28), 0.19 (0.11 to 0.31) and 0.21 (0.14 to 0.30), respectively. The median (IQR) S6K activity 
in the NTG, OHT and control groups, was 0.49 (0.45 to 0.64), 0.45 (0.32 to 0.52) and 0.51 (0.45 to 
0.68), respectively, while the median (IQR) 4EBP1 activity was 1.26 (1.02 to 1.46), 1.15 (1.07 to 1.40) 
and 1.08 (0.70 to 1.23), respectively.  
 
Conclusions 
In view of the increasing evidence linking mitochondrial efficiency with glaucoma resistance and the 
central role of mTOR in regulating mitochondrial biogenesis, the purpose of this study was to 
determine whether differences in mitochondrial function between OHT and NTG patients could be 
explained by activity in the mTOR pathway. To gain useful insight into the mTOR-regulating cellular 
mechanisms, the most important upstream and downstream targets of mTOR were measured in this 
unique, prospectively selected cohort. In this series, despite the higher systemic mitochondrial 
activity in OHT patients compared to the NTG patients, there was no significant difference in the 
systemic PTEN-Akt1-mTOR-S6K-4EBP1 pathway activity between the three groups, suggesting that 
this pathway may not play a central role in mitochondrial efficiency in OHT. Nevertheless, a weak 
trend was observed for lower mTOR activity in OHT as compared to the other two groups, with an 
associated lower S6K and higher 4EBP1 activity in OHT. This is in line with a recent study showing 
that mTOR inhibition by rapamycin dramatically promotes RGC survival in a rat chronic ocular 
hypertension model, due to the inhibition of neurotoxic mediators’ release and direct suppression of 
RGC apoptosis (Su 2014). This protective effect of rapamycin appears to contradict other studies that 
have linked mTOR suppression with lower mitochondrial function (Ramanathan 2009, Schieke 2006), 
although the use of different stressors and different animal and cell models in each study make 
direct comparisons difficult. mTOR is a versatile regulator that responds to a variety of cellular and 
extracellular stimuli, such as hypoxia, inflammation, low ATP levels, growth factors and  
neurotransmitters, and its role in health and disease and also during different stages of development 
is still poorly understood. 
Although this study explores several major upstream and downstream mTOR targets, it is important 
to note the complexity of these mechanisms at a cellular level and the multiple interactions of these 
targets with other, still unexplored, pathways. Therefore, the absence of any significant difference in 
the PTEN-Akt1-mTOR-S6K-4EBP1 pathway between the three groups of participants, should not be 
interpreted as weakening the link between mitochondrial dysfunction and glaucoma or between 
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mitochondrial efficiency and glaucoma resistance, and should not minimise the potentially 
important role in the pathogenesis of glaucoma of other molecular targets interacting with this 
pathway. As an example, PTEN, a negative regulator of mTOR, and SOCS3 (suppressor of cytokine 
signalling 3), a negative regulator of the Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT) signalling pathway, have been shown to regulate two independent pathways, 
which however enable robust and sustained long-distance axon regeneration in the adult central 
nervous system only when acting synergistically. While either PTEN or SOCS3 deletion in adult 
mouse RGCs individually promotes significant optic nerve regeneration following crush injury, such 
re-growth tapers off around two weeks after the insult, whereas simultaneous deletion of both PTEN 
and SOCS3 enables significant and prolonged axon regeneration (Sun 2011). Alternative pathways to 
be explored in future studies may include other important negative regulators of mTOR function, 
such as the tuberous sclerosis complex (TSC1/2). Hypoxia activates TSC1/2 through the regulated in 
development and DNA damage response (REDD) proteins leading to loss of mTOR function, while 
Akt and the extracellular-signal regulated kinases 1/2 (ERK1/2) inactivate TSC1/2 leading to mTOR 
stimulation (Di Polo 2015). Also, in view of the recent evidence of increased mitochondrial 
biogenesis in LHON carriers, it would be interesting for future studies to explore the role of PGC1α, a 
master regulator of mitochondrial biogenesis and downstream mTOR target within the mTOR-YY1-
PGC1α pathway, in patients with OHT. 
The utility of lymphoblasts to investigate mitochondrial dysfunction in optic neuropathies has been 
demonstrated previously in studies that determined oxphos defects in Leber’s hereditary optic 
neuropathy (Brown 2001), autosomal dominant optic atrophy (Van Bergen 2011) and primary open 
angle glaucoma (Lee 2012). Unlike previous studies, a significant advantage of our approach was the 
use of unstimulated PBMCs (Lascaratos 2015), thus providing a more ‘pure’ human model that 
minimises any potential effect of viral transformation on measurements of mitochondrial function.  
Another major strength of this study was its prospective and unique design, where patients at the 
very extremes of IOP susceptibility (fast progressing NTG with low IOP and non- or slow- progressing 
OHT with high IOP) were compared to age-similar controls. Although the small cohort size may limit 
the generalisability of our findings, the design employed here would be expected to maximise our 
chances of detecting mitochondria-related differences between groups. Also, instead of looking at 
the mTOR pathway at a single cellular level, we aimed to confirm our findings by measuring the 
activity of the most important upstream (PTEN, Akt1) and downstream (S6K, 4EBP1) mTOR targets. 
With regards to co-existing systemic diseases, a reduction in the systemic mTOR activity has been 
associated with diabetes (Fraenkel 2008), with mTOR activation thought to promote the secretion of 
insulin and increase insulin sensitivity (Chong 2012). Yet, mTOR may also act via a negative feedback 
loop that can lead to poor insulin signalling and insulin resistance. Only one OHT patient (no 5) in our 
cohort suffered from diabetes (controlled on diet) and her mTOR activity was not particularly low at 
0.19, coinciding with the median mTOR activity for this group. Also, it is unclear to what extent this 
condition would have affected mitochondrial function in the PBMCs. The latter may not be as 
critically involved in the pathophysiology of certain diseases as other tissues, and diabetes has been 
linked to mitochondrial dysfunction in insulin-sensitive tissues, including myocytes (Kelley 2002), 
hepatocytes (Sivitz 2010) and adipocytes (Choo 2006), but not in PBMCs. Also, the relatively short 
half-life of PBMCs (usually days to month) and their relatively high turnover would likely minimise 
the accumulating impact of chronic diseases on mTOR activity. Moreover, the role of mTOR as a 
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regulator of metabolism is well established and, while a relatively higher BMI was noted in the OHT 
group, the difference in the BMI between the three groups was not significant. A single OHT patient 
(no 1) showed a very high BMI (40.9) and even after excluding this individual from the analysis, no 
difference was found in the mTOR activity between the three groups. 
Another systemic condition thought to be positively associated with mTOR activity is cancer, with 
increasing evidence that mTOR can drive tumourigenesis by activating Akt1, which promotes 
proliferation, survival and nutrient uptake in cancer cells (Zoncu 2011). Also, tumours can be driven 
by mutations in the tumour suppressor gene PTEN or by oncogenic mutations in PI3K, which 
promotes Akt1 signalling. However, these processes are likely to be more complex than we currently 
understand and perhaps apply only to the tissue of interest (and not PBMCs) or to specific types of 
cancers or specific stages in the disease process. The only participant in our study (control no 3) with 
active malignancy (breast cancer recently diagnosed at the time of blood sampling) showed a 
relatively low mTOR activity at 0.15, with the median in the control group being 0.33. Even after 
excluding the four patients with history of cancer (control no 3 and OHT no 1, 2 and 3) from the 
analysis, no significant difference in the mTOR activity was noted between the three groups. Perhaps 
it is more relevant to note than none of the participants suffered from active haematological 
malignancy or had undergone recent chemotherapy, factors which, if present, might have impacted 
more directly on PBMC function.  
Unlike systemic diseases such as cancer and diabetes, glaucoma is a multifactorial disease of the 
optic nerve and it would perhaps not be surprising if systemic (peripheral blood) mTOR 
dysregulation was not a dominant risk factors in our NTG cohort. In some patients, other risk factors 
(such as vascular) may predominate and this could explain the lack of differences between the NTG 
and control groups. Also, while an increased vulnerability to widespread neurodegenerative disease 
has been reported in glaucoma, including a temporal processing defect in the auditory pathways 
(Rance 2012), none of our NTG patients had any co-existing neurodegenerative diseases, such as 
Parkinson’s disease or dementia. The potential impact of topical medications on measurements was 
also considered, although there is no evidence to date to suggest that drugs applied topically would 
have a major impact on human circulating PBMCs. In terms of systemic medications, while aspirin 
has been linked to mTOR suppression (Spampatti M et al 2014), only two patients in our cohort (NTG 
no 5 and no 6) were on aspirin and after excluding these individuals from the analysis no significant 
difference was noted in the mTOR activity between the three groups.  
The link between mTOR and vasospasm is new and interesting. The only patient in our cohort with a 
history of Raynaud’s showed significantly higher mTOR activity, which is consistent with previous 
reports. mTOR inhibitors have been shown to decrease hypoxia inducible factor 1α (HIF1α) levels 
(Faivre 2006), while HIF1a inhibition is known to reduce the cerebral vasospasm following 
subarachnoid haemorrhage in rats and attenuate the expression of its downstream target vascular 
endothelial growth factor (VEGF) (Yan 2006). VEGF is a potent stimulant of angiogenesis and is 
involved in the pathogenesis of cerebral vasospasm (Borel 2003). Also, treatment with the mTOR 
inhibitors rapamycin and AZD8055 leads to the attenuation of angiographic vasospasm and 
improvement in clinical behavioural scores (Zhang 2012). As part of this study, a single case is 
presented that supports the above link between mTOR and vasospasm.  
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Figure 1: Schematic of the PTEN-Akt1-mTOR signalling pathway (modified from Liu et al 2012) 
 
 
 
 
 
           Complex I                Complex II 
 
Figure 2: The rate of ADP phosphorylation (pmol/min/mg) by mitochondrial respiratory complex I 
and complex II in the PBMC from NTG and OHT patients, and age-similar controls (n= 7 from each 
group). The median (IQR) rate of ADP phosphorylation by complex I in the control, NTG and OHT 
groups, was 4712 (3856-7732), 6063 (3016-8649) and 11237 (5716-12576), respectively (P=0.063 
between control-OHT, P=0.018 between NTG-OHT and P=0.866 between control-NTG). The median 
(IQR) rate of ADP phosphorylation by complex II in the control, NTG and OHT groups, was 6712 
(3962-8472), 7018 (3077-9897) and 11277 (6131-12285), respectively (P=0.128 between control-
OHT, P=0.018 between NTG-OHT and P=0.612 between control-NTG).  
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Figure 3: The PTEN-Akt1-mTOR pathway activity in the PBMC from NTG and OHT patients, and age-
similar controls (n=7 from each group). All results are expressed as the ratio between the 
phosphorylated (PS380-PTEN, PS473-Akt1 and PS2448-mTOR) and total PTEN, Akt1 and mTOR, 
respectively. 
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Figure 4: The activity of the two main mTOR downstream targets (4EBP1 and S6K) in the PBMC from 
NTG and OHT patients, and age-similar controls (n=7 from each group). All results are expressed as 
the ratio between the phosphorylated (PT37/46-4EBP1 and PT389-S6K) and total 4EBP1 and S6K, 
respectively. 
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Table 1: Demographic and other baseline clinical data for control, NTG and OHT subjects.  
 
Variable Control (n=7) NTG (n=7) OHT (n=7) 
Mean age (±SD) 65.3 (±7.1) 70.7 (±20.0) 70.6 (±11.0) 
Ethnicity (white) 7 5 7 
Median (IQR) VF 
progression rate  
n/a -1.07 (-1.05 to -1.09) -0.15 (-0.14 to -0.21) 
Median number of VFs 
(IQR) 
n/a 9 (8.5 to 11) 8 (8 to 11) 
Median years of follow-up 
(IQR) 
n/a 6 (5.8 to 6.5) 8 (6.5 to 11.1) 
Mean GAT IOP during 
follow-up  
n/a 12.9  24.5  
Mean maximum reported 
GAT IOP  
n/a 19.3 31.7 
Mean cup-to-disc ratio 0.36 0.91 0.56 
NTG: normal tension glaucoma; OHT: ocular hypertension; SD: standard deviation; IQR: interquartile 
range; GAT: Goldmann applanation tonometry; IOP: intraocular pressure; VF: visual field; n/a: not 
applicable. IOP is measured in mmHg and VF progression is expressed in decibels (dB) per year. 
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Table 2: Past medical history and vascular factors in the cohort. 
 Control NTG OHT 
Diabetes  0 0 1 
Cancer 1 0 3* 
Extreme dippers 0 0 1 
BMI (mean ± SD) 22.8 ± 2.9 22.8 ± 3.7 27.1 ± 7.5 
HT 0 3 4 
NSAIDs 0 2 0 
Statins 1 2 2 
Other (CVA, MI) 1 0 0 
Raynaud’s or 
vasospasm 
0 1 0 
Migraine 1 0 0 
HT: systemic hypertension; CVA: cerebrovascular accident; MI: myocardial infarction; BMI: body 
mass index; NSAIDs: non-steroidal anti-inflammatory drugs; extreme dippers defined as subjects 
whose mean night time systolic blood pressure was more than 20% lower compared to the mean 
day time ambulatory systolic blood pressure; *history of cancer many years prior to study with no 
evidence of recurrence 
ACCEPTED MANUSCRIPT
